Source: Lieyun Network
Recently, VIVAVISION announced the completion of a D2+ round of financing worth 140 million yuan, with the investor being Wenzhou Ouhai Xiangtou Yicun Equity Investment Partnership (Limited Partnership), a fund under Ouhai Science and Technology Investment Company.
VIVAVISION is an ophthalmic innovative drug developer, focusing on the clinical-stage development of novel therapeutics in the field of ophthalmology. It has established a unique platform for ophthalmic drug innovation and multiple self-developed novel drugs have entered or are about to enter the clinical stage. The company's main product is Lifitegrast, a treatment for dry eye disease, which has been approved by the FDA.